Volasertib (BI 6727)

For research use only. Not for use in humans.

Catalog No.S2235

59 publications

Volasertib (BI 6727) Chemical Structure

Molecular Weight(MW): 618.81

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 202 In stock
USD 120 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Volasertib (BI 6727) has been cited by 59 publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.
Features A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.
Targets
PLK1 [1]
(Cell-free assay)
0.87 nM
In vitro

Like BI2536, BI6727 is an ATP-competitive kinase inhibitor from the dihydropteridinone class of compounds. In addition to Plk1, BI6727 also potently inhibits two closely related kinases Plk2 and Plk3 with IC50 of 5 nM and 56 nM, respectively. BI6727 at concentrations up to 10 μM displays no inhibitory activity against a panel of >50 other kinases. BI6727 inhibits the proliferation of multiple cell lines derived from various cancer tissues, including HCT116, NCI-H460, BRO, GRANTA-519, HL-60, THP-1, and Raji cells with EC50 of 23 nM, 21 nM, 11 nM, 15 nM, 32 nM, 36 nM, and 37 nM, respectively. BI6727 treatment (100 nM) in NCI-H460 cells induces an accumulation of mitotic cells with monopolar spindles and positive staining for histone H3 phosphoserine 10, confirming that cells are arrested early in the M phase, followed by induction of apoptosis. [1] Low nanomolar concentrations of BI6727 display potent inhibitory activity against neuroblastoma (NB) tumor-initiating cells (NB TIC) with EC50 of 21 nM, whereas only micromolar concentrations of BI6727 are cytotoxic for normal pediatric neural stem cells. [2] BI6727 induces growth arrest of Daoy and ONS-76 medulloblastoma cells similar to BI 2536. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KASUMI-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:3NkBp NGr1WGdKSzVyPUG3NOKyPTFibl2= MmLnNlU2PzZyN{S=
KG-1 MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe3NkBp M3TwVWlEPTB;MUWwxtE3PyCwTR?= MXKyOVU4PjB5NB?=
MOLM-13 NVXZVHlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3MO|IhcA>? NXrldnU{UUN3ME21O:KyPDRibl2= M3rwWlI2PTd4MEe0
MV-4-11 M4jFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjYR4o4OiCq NGPEWphKSzVyPUG2xtE3KG6P MXGyOVU4PjB5NB?=
NOMO-1 NXLjXYppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL6[YRMPzJiaB?= NITsSJJKSzVyPUG0OeKyPyCwTR?= MoL2NlU2PzZyN{S=
OCI-AML3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrqUXg4OiCq NVL4fHFbUUN3ME25NOKyPTFibl2= Mn;vNlU2PzZyN{S=
SKM-1 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fMOlczKGh? NX7XbnZXUUN3ME25OeKyPTJibl2= NXH5SIluOjV3N{[wO|Q>
THP-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELzc|U4OiCq MkjBTWM2OD13NtMxN|khdk1? M4naNFI2PTd4MEe0
MCF7/LTED  M{P4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTDVIZyOi53LUSwJI5O MoPJOUBl M176XIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXT2cWo1OjV2OEC5OFM>
HCC1428/LTED MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\Ze3AzNjVvNECgcm0> M{\4[FUh\A>? MlG4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Ml;ENlU1QDB7NEO=
A431 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LvU|AuOzBibl2= M37oUVEuPCCm M1nQUolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MlTJNlM5QTFyOU[=
FaDu  NInaPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvzSHQxNTFyMECgcm0> M{\6bVEuPCCm NH3TSIRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MnHFNlM5QTFyOU[=
SF188 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH6[pM2OC1zNUCgcm0> Mn;HO|IhcA>? M4fsWWROW09? M4nOcYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> Mnr5NlM5QDd4NEW=
T98G MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\GSIdYPTBvMUWwJI5O MVO3NkBp M{O4ZWROW09? MYfpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= MVqyN|g5PzZ2NR?=
DU145 MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfvNVAwPTBxMkWwJI5O NFX6bFczPCCq M{jBTWlEPTB:MUCgcm0> M4Dt[VI{QDh2NEK4
LNCaP M370d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLQcYsyOC93MD:yOVAhdk1? M3jNO|I1KGh? MWLJR|UxRDFyIH7N MV2yN|g5PDR{OB?=
PC3 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HxWFExNzVyL{K1NEBvVQ>? NHLu[WgzPCCq M{PaOmlEPTEkiMy2NFAhdk1? MVyyN|g5PDR{OB?=
RT4 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XNT|Q5KGh? NYftdG9SUUN3ME2xNVEvOjdibl2= NWqzPVBFOjN5OUK2N|k>
5637 NWH6OZpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\CelQ5KGh? MmjiTWM2OD1zMU[1MlE1KG6P NIDsWHkzOzd7Mk[zPS=>
T24 NVLzZ5FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\vOpc1QCCq M{nsSGlEPTB;MkC0MlkyKG6P M132OVI{Pzl{NkO5
KMCH-1 NYn5bmxVSXCxcITvd4l{KEG|c3H5 M33lW|IxOCCwTR?= Mn\MNlQhcA>? NYP5cHNvcW6mdXPld{BieG:ydH;zbZM> M4X5VlI{PzB|Nkez
Mz-ChA-1 Mlf0RZBweHSxc3nzJGF{e2G7 NUP5NHMyOjByIH7N M1jHdFI1KGh? M3Hi[4lv\HWlZYOgZZBweHSxc3nz MofMNlM4ODN4N{O=
HUCCT-1 MnTFRZBweHSxc3nzJGF{e2G7 M3;E[VIxOCCwTR?= NILDZmUzPCCq MkPYbY5lfWOnczDhdI9xfG:|aYO= NHHac2szOzdyM{[3Ny=>
HCT 116 NFHTcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\NSFN3TUN3MNMgQUAzOyCwTR?= MWixPVM5Ozh{Mx?=
NCI-H460 M3LRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\6VGVEPTEEoE2gNlEhdk1? MXWxPVM5Ozh{Mx?=
BRO MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HteGVEPTEEoE2gNVEhdk1? NEDqcpIyQTN6M{iyNy=>
GRANTA-519 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jVeGVEPTEEoE2gNVUhdk1? MnvlNVk{QDN6MkO=
HL-60 NHrrNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT0SWM2OMLiPTCzNkBvVQ>? MV[xPVM5Ozh{Mx?=
THP-1 NVfsN3k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIntOnpGSzVyIE2gN|Yhdk1? MmDiNVk{QDN6MkO=
Raji NHTte2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LYeGVEPTBiPTCzO{BvVQ>? M1;KSlE6Ozh|OEKz

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-PLK1 / PLK1; 

PubMed: 29108241     


The protein expression of PLK1 and its phosphorylation levels at 24 hours after volasertib treatment in HL-60 and K562 cells.

p-AKT / AKT / p-MAPK / MAPK; 

PubMed: 29108241     


Phosphorylation levels of AKT and MAPK in AML cell lines after volasertib administration.

PARP / c-myc; 

PubMed: 29383095     


Treatment with volasertib (24 hours) induces PARP cleavage and decreases total c-myc expression in the indicated lymphoma cell lines. From left to right: diffuse large B-cell lymphomas (DLBCL), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL) and, peripheral T-cell lymphomas non-otherwise specified (PTCL-NOS). Protein expression was evaluated by immunoblotting.

p-c-Met / c-Met / p-FAK / FAK / p-Src / Src ; 

PubMed: 31040125     


The same cell lines treated identically were subjected to immunoblotting for the indicated proteins (upper) with densitometric quantification normalized with b-actin (lower).

Fibronectin / β-integrin / p-vimentin / Vimentin / p-HH3; 

PubMed: 31040125     


Epithelial and mesenchymal non-small-cell lung cancer (NSCLC) cell lines after treatment with 50 nM volasertib for 24 h. Cells were then harvested, and lysates were immunoblotted for the indicated proteins.

29108241 29383095 31040125
Immunofluorescence
PLK1 / Wee1; 

PubMed: 29108241     


The protein expressions of PLK1 and Wee1 were evaluated by immunofluorescent staining. Both parental and volasertib-resistant MOLM14 and HL-60 cells were treated with 50 nM volasertib for 18 hours.

29108241
Growth inhibition assay
Cell viability; 

PubMed: 29383095     


Survival of different B-cell and T-cell lymphoma cell lines upon treatment with indicated doses of Volasertib at 72 hrs. 

29383095
In vivo Administration of BI6727 significantly inhibits the growth of multiple human carcinoma xenografts including HCT116, NCI-H460, and taxane-resistant CXB1 colon carcinoma, accompanied by an increase in the mitotic index as well as an increase in apoptosis. [1] In in vivo studies, BI6727 shows better toxicity and pharmacokinetic profile compared to BI2536. [3]

Protocol

Kinase Assay:[1]
- Collapse

In vitro kinase assays:

Recombinant human Plk1 (residues 1-603) is expressed as NH2-terminal, GST-tagged fusion protein using a baculoviral expression system and purified by affinity chromatography using glutathione-agarose. Enzyme activity assays for Plk1 are done in the presence of serially diluted BI6727 using 20 ng of recombinant kinase and 10 μg casein from bovine milk as substrate. Kinase reactions are done in a final volume of 60 μL for 45 minutes at 30 °C [15 mM MgCl2, 25 mM MOPS (pH 7.0), 1 mM DTT, 1% DMSO, 7.5 μM ATP, 0.3 μCi γ-32P-ATP]. Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transferring the precipitates to MultiScreen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curves are used for calculating IC50 value.
Cell Research:[1]
- Collapse
  • Cell lines: HCT116, NCI-H460, BRO, GRANTA-519, HL-60, THP-1, and Raji
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cell proliferation assays are done by incubating cells in the presence of various concentrations of BI6727 for 24, 48, and 72 hours and cell growth is assessed by measuring Alamar blue dye conversion in a fluorescence spectrophotometer. Effective concentrations at which cellular growth is inhibited by 50% (EC50) are extrapolated from the dose-response curve fit. To determine the DNA content, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide in PBS for 20 minutes at room temperature. Cell cycle profiles are determined by flow cytometric analysis.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female BomTac:NMRI-Foxn1nu mice grafted s.c. with HCT116, NCI-H460, or CXB1 cells
  • Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl, or suspended in 0.5% Natrosol 250 hydroxyethyl-cellulose
  • Dosages: ~25 mg/kg/day
  • Administration: Injected i.v., or given intragastrally via gavage needle
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL warmed (32.32 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+corn oil
For best results, use promptly after mixing. 		2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 618.81
Formula

C34H50N8O3
CAS No. 755038-65-4
Storage powder
in solvent
Synonyms N/A
Smiles CCC1N(C(C)C)C2=C(C=NC(=N2)NC3=CC=C(C=C3OC)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)N(C)C1=O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02722135 Withdrawn Drug: Volasertib Leukemia Myeloid Acute Boehringer Ingelheim November 2016 Phase 1
NCT02721875 Terminated Drug: Volasertib|Drug: Azacitidine Myelodysplastic Syndromes Boehringer Ingelheim April 28 2016 Phase 1
NCT02201329 Completed Drug: Azacitidine|Drug: Volasertib Myelodysplastic Syndromes|Leukemia Myelomonocytic Chronic Boehringer Ingelheim August 2014 Phase 1
NCT01971476 Completed Drug: volasertib Leukemia|Neoplasms Boehringer Ingelheim October 22 2013 Phase 1
NCT01662505 Completed Drug: Volasertib Leukemia Myeloid Acute Boehringer Ingelheim August 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I wonder how to reconstitute the inhibitor for in vivo studies?

  • Answer:

    Volasertib can be dissolved in 4% DMSO+Corn oil at 2mg/ml for i.p. injection in mice. For oral administration, it can be formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl, or suspended in 0.5% Natrosol 250 hydroxyethyl-cellulose as indicated in the publications. We also suggest the vehicle 30% PEG400/0.5% Tween80/5% propylene glycol for a suspension which we tested in house.

selleck catalog

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

  • Pan Plk Inhibitors

    BI 2536 : Pan-Plk1, Plk1, IC50=0.83 nM; Plk2, IC50=3.5 nM; Plk3, IC50=9 nM.

  • Most Potent Plk Inhibitor

    BI 2536 : Plk1, IC50=0.83 nM.

  • Plk Inhibitor in Clinical Trial

    Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).

  • Newest Plk Inhibitor

    Ro3280 New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Related PLK Products

  • SBE 13 HCl New

    SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • CCG-1423 New

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.

  • BI 2536

    BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

    Features:The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

  • Rigosertib (ON-01910)

    Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.

  • HMN-214

    HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

  • GSK461364

    GSK461364 inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

    Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.

  • MLN0905

    MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.

  • Ro3280

    RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

    Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.

  • NMS-P937 (NMS1286937)

    NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Tags: buy Volasertib (BI 6727) | Volasertib (BI 6727) supplier | purchase Volasertib (BI 6727) | Volasertib (BI 6727) cost | Volasertib (BI 6727) manufacturer | order Volasertib (BI 6727) | Volasertib (BI 6727) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID